Business
Availability of Report & Acco
Availability of Report & Acco.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n RNS Number : 8146C Sareum Holdings PLC 20 November 2009 \n \n\n\n\n\n(AIM: SAR)\n\n\n20 November 2009\n\n\n\n\n\nSAREUM HOLDINGS PLC(\"Sareum\" or the \"Company\") \nAvailability of Report & Accounts\n\nThe Company announces that the report and accounts for the year ended 30 June 2009 has now been posted to shareholders and is available from the Company's website www.sareum.co.uk.\n\n\n\n\n\nSareum Holdings plc\n\n\n\n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\n\n\n\n\n\n\n\n\nMerchant John East Securities Limited (Nominated Adviser)\n\n\n\n\nSimon Clements/Bidhi Bhoma\n\n\n020 7628 2200\n\n\n\n\n\n\n\n\n\n\n\n\nHybridan LLP (Broker)\n\n\n\n\n\n\n\nClaire Noyce/Stephen Austin\n\n\n020 3159 5085\n\n\n\n\n\nNotes for editors: \n\nAbout Sareum Holdings plc\n\nSareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer.\n\nSareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.\n\nSareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR. For further information, please visit www.sareum.co.uk\n\nThis information is provided by RNSThe company news service from the London Stock Exchange END ACSCKCKDOBDDFDD\n ","length":4138,"tagName":"div"}]